Psychophysical Studies of Cancer Therapy-Induced Pain
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Psychophysical Studies of Cancer Therapy-Induced Pain: A Feasibility Study|
- Participant Heat + Cold Pain Threshold [ Time Frame: 1 Hour Sensory Testing: Baseline + testing at repeated intervals throughout chemotherapy or at later follow-ups. ] [ Designated as safety issue: No ]
- Participant Mechanical Testing Results <Touch Detection Threshold; Sharpness Threshold + Pain Ratings to Needle Probe; Bump Test> [ Time Frame: 1 Hour Sensory Testing: Baseline + testing at repeated intervals throughout chemotherapy or at later follow-ups. ] [ Designated as safety issue: No ]
|Study Start Date:||January 2001|
|Estimated Primary Completion Date:||January 2018 (Final data collection date for primary outcome measure)|
Cancer Therapy-Induced Pain
Patients with advanced cancer entering chemotherapy or have reported pain as a result of cancer treatment.
Other: Sensory Tests
Tests to find the threshold at which perceive stimuli.
Participants will be contacted either before their initiation of chemotherapy or following their referral to pain management service for neuropathic cancer treatment-related pain.
The sensory tests will take about 1 hour to complete. These tests will seek to find the threshold (a measure of sensitivity) at which you perceive stimuli, such as touch, coolness, warmth, hot/cold feeling and pinprick. You will be asked to rate the intensity of each of these stimuli that you perceive to be painful. You will also be asked to rate the intensity of stimuli that are at a fixed intensity above the pain threshold for most people.
You may either be tested at repeated intervals throughout your chemotherapy or at later follow-up dates to check the length of symptoms.
Length of Study:
Your participation will be complete once you have completed all the sensory testing.
This is an investigational study. A total of 450 patients will be enrolled in this study. All will be enrolled at MD Anderson.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00515060
|Contact: Patrick M. Dougherty, PhD||713-745-0438|
|United States, Texas|
|University of Texas MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator: Patrick M. Dougherty, PhD|
|Principal Investigator:||Patrick M. Dougherty, PhD||M.D. Anderson Cancer Center|